SGLT2 Inhibitor Brand Names
The four FDA-approved SGLT2 inhibitors available in the United States are empagliflozin (Jardiance), canagliflozin (Invokana), dapagliflozin (Farxiga), and ertugliflozin (Steglatro). 1, 2
Available SGLT2 Inhibitors by Generic and Brand Name
Empagliflozin
- Brand name: Jardiance 3
- Available in 10 mg and 25 mg tablets 3
- FDA-approved to reduce cardiovascular death in adults with type 2 diabetes and established cardiovascular disease 1
Canagliflozin
- Brand name: Invokana 1
- Available in 100 mg and 300 mg doses 1
- Demonstrated cardiovascular benefits in the CANVAS trials 1
Dapagliflozin
Ertugliflozin
- Brand name: Steglatro 1, 2, 4
- Newer agent in the SGLT2 inhibitor class 1
- Has similar mechanism of action to other SGLT2 inhibitors 2
Additional SGLT2 Inhibitor (Not Widely Available in US)
Sotagliflozin
- Dual SGLT1/SGLT2 inhibitor with different selectivity profile than the four agents above 4, 5
- Has been studied in cardiovascular outcome trials 5
Key Clinical Considerations
All four agents work by the same mechanism: blocking sodium-glucose cotransporter 2 in the proximal renal tubule to increase urinary glucose excretion 2, 3, 6
Cardiovascular benefits vary by agent: Empagliflozin and canagliflozin have the strongest evidence for reducing major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease 1
Renal function affects efficacy: Glucose-lowering efficacy diminishes as eGFR falls below 45 mL/min/1.73 m², though cardiovascular and renal benefits persist down to eGFR 30 mL/min/1.73 m² 1, 4, 3
Agent-specific safety concerns: Canagliflozin has been associated with increased amputation risk and bone fractures in some trials, while empagliflozin and dapagliflozin have not shown these signals 1